Support for the Resumption of Training of High-level Athletes Post-epidemic COVID-19 (ASCCOVID19)
22 juin 2021 mis à jour par: University Hospital, Bordeaux
As of March 2020, COVID-19 has become a global pandemic, halting athletic competition worldwide.
Reports from China show a high prevalence of cardiac involvement in patients with severe SARS-CoV-2 infection. These cardiac forms were found to be closely associated with adverse outcomes. The use of Magnetic resonance Imaging (MRI) had allowed to show that cardiac dysfunction could be mediated by myocardial inflammation (i.e. myocarditis). The direct implication of the virus was demonstrated with Severe Acute Respiratory Syndrome (SARS)-CoV-2 being detected on myocardial biopsies in a patient with severe heart failure.
The experience with other viruses causing acute myocarditis shows that there is a high rate of undetected injuries. Indeed, although severe heart failure can be present at the acute stage, acute viral myocarditis is most commonly pauci or asymptomatic, but still leaving occult myocardial scars visible on MRI, and exposing to higher risks of ventricular arrhythmia and sudden cardiac death over the long term.
Although athletes are younger and have fewer comorbidities than the general population and therefore are at lower risk for severe disease or death, there is a critical and urgent need to assess the prevalence of occult scars in the population of high-level athletes returning to training after the SARS-CoV-2 pandemia.
Aperçu de l'étude
Statut
Complété
Les conditions
Type d'étude
Interventionnel
Inscription (Réel)
984
Phase
- N'est pas applicable
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
-
Angoulême, France, 16000
- Training center Soyaux Angoulême XV Rugby
-
Aurillac, France, 15000
- Training Center Stade Aurillacois
-
Bayonne, France, 64104
- Aviron Bayonnais Rugby Pro Training Center
-
Biarritz, France, 64200
- Biarritz Olympique Pays Basque training center
-
Bordeaux, France, 33076
- Bordeaux University Hospital - CRB medical office - Hôpital du Tondu
-
Bordeaux, France, 33076
- Bordeaux University Hospital - Service UDH - Hôpital Pellegrin
-
Brive-la-Gaillarde, France, 19100
- CABCL Rugby Training Center
-
Bègles, France, 33130
- Union Bordeaux-Bègles training center
-
Carcassonne, France, 11000
- US Carcassonne Rugby training center
-
Colomiers, France, 31770
- Union Sportive Colomiers Rugby training center
-
Grenoble, France, 38100
- FC Grenoble Rugby training center
-
La Rochelle, France, 17000
- Stade Rochelais Rugby training center
-
Le Plessis-Robinson, France, 92350
- Racing92 training center
-
Montauban, France, 82000
- AS Montauban Rugby training center
-
Nevers, France, 58000
- US Nevers Rugby training center
-
Paris, France, 75016
- Stade Français training center
-
Pau, France, 64000
- Section Paloise Rugby training center
-
Perpignan, France, 66000
- USAP Training Center
-
Romans-sur-Isère, France, 26100
- Training center Valence Romans Drôme Rugby
-
Saix, France, 81710
- Castres Olympique training center
-
Toulouse, France, 31200
- Stade Toulousain Rugby training center
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
18 ans et plus (Adulte, Adulte plus âgé)
Accepte les volontaires sains
Oui
Sexes éligibles pour l'étude
Tout
La description
Inclusion Criteria:
- High level athlete,
- Of both sexes and age ≥ 18 years,
- Affiliated to or beneficiary of a social security system,
- Free, informed, written consent signed by the participant and the investigating physician (no later than the day of inclusion and before any examination required by the research),
- Effective method of contraception for women with childbearing capacity.
Exclusion Criteria:
- Minor,
- History of ventricular arrhythmia, myocarditis, identified coronary artery disease or documented myocardial fibrosis,
- Pregnant or breastfeeding women,
- Person unable to give informed consent,
- Person deprived of liberty by judicial or administrative decision,
- Adults subject to a legal protection measure (guardianship, curator, safeguard of justice).
Specific exclusion criteria for the MRI component (Contraindications):
- Subject with an implantable pacemaker or defibrillator, intraocular metallic foreign body, intracranial metallic clip, pre 6000 Starr-Edwards type cardiac valve prosthesis, or biomedical device such as insulin pump or neurostimulator,
- Hypersensitivity to gadolinium or to one of the excipients of the contrast product used,
- Claustrophobic subjects or those unable to remain in an immobile lying position for 30 minutes,
- Renal insufficiency with creatinine clearance of less than 30 ml/min,
- A patient whose shoulder width does not allow installation in the MRI machine.
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: High-level athletes
High level athletes are rugby players, intervention unit agents of the National Police, sports students. Definition of a COVID-19 positive subject : Any subject whose serology is positive (IgM and/or IgG) and/or the Reverse Transcription Polymerase Chain Reaction (RT-PCR) result is positive and/or the questionnaire is positive and/or a new electrocardiogram (ECG) abnormality. The COVID-19 negative subjects do not meet the definition of COVID-19 positive subjects. |
An ECG at rest is performed for all participants at Day 0. A centralized reading is performed by one of the 6 expert cardiologists participating in the research.
In case of positive COVID-19 serology and/or positive COVID-19 RT-PCR and/or new ECG abnormality and/or positive questionnaire, a stress test is performed.
In case of positive COVID-19 serology and/or positive COVID-19 RT-PCR and/or new ECG abnormality and/or positive questionnaire, a Cardiac echocardiography is performed.
In case of positive COVID-19 serology and/or positive COVID-19 RT-PCR and/or new ECG abnormality and/or positive questionnaire, a Cardiac rhythm monitoring is performed.
To determine the rhythmic risk of athletes
High resolution MRIs is performed on 200 athletes :
For all athletes included at the D0 inclusion visit, a centralized COVID-19 serology is performed to search for biomarkers associated with the occurrence of myocardial fibrosis: analysis of genetic determinants in relation to cardiac damage. For athletes who have performed MRI: Search for biomarkers associated with the occurrence of myocardial fibrosis: analyses of low-grade inflammation markers (cytokine assay and fibrosis markers). |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Presence of rhythmic risk markers bye the questionnaire
Délai: Day 0
|
Questionnaire looking for heart palpitations, chest pain/pressure and shortness of breath.
|
Day 0
|
|
Evaluation by resting ECG of rhythmic risk marker : repolarization disorders
Délai: Day 0
|
Presence or absence of repolarization disorders
|
Day 0
|
|
Evaluation by resting ECG of rhythmic risk marker : inverted T waves
Délai: Day 0
|
Presence or absence of inverted T waves
|
Day 0
|
|
Evaluation by resting ECG of rhythmic risk marker : ST segment abnormalities
Délai: Day 0
|
Presence or absence of ST segment abnormalities
|
Day 0
|
|
Evaluation by resting ECG of rhythmic risk marker : QRS fragmentation
Délai: Day 0
|
Presence or absence of QRS fragmentation
|
Day 0
|
|
Evaluation by resting ECG of rhythmic risk marker : ventricular extrasystoles (VES)
Délai: Day 0
|
Presence or absence of VES.
Ventricular extrasystoles especially with short coupling (<300ms), falling on the T wave, width > 160ms, complex forms (repetitive, several morphologies, instantaneous cycle >200bpm)
|
Day 0
|
|
Evaluation by resting ECG of rhythmic risk marker : ventricular tachycardia (VT)
Délai: Day 0
|
Presence or absence of VT.
|
Day 0
|
|
Presence of rhythmic risk markers bye the stress test
Délai: Day 0
|
VES, especially with short coupling (<300ms), falling on the T wave, width > 160ms, complex shapes (repetitive, several morphologies, instantaneous cycle >200bpm), ventricular tachycardias (VT).
The analysis focus on the exercise period, and the recovery period.
Ventricular arrhythmias will be quantified.
|
Day 0
|
|
Presence of rhythmic risk markers bye ECG holter
Délai: Day 0
|
VES, especially with short coupling (<300ms), falling on the T wave, width > 160ms, complex shapes (repetitive, multiple morphologies, instantaneous cycle >200bpm), ventricular tachycardias (VTs).
Ventricular arrhythmias are quantified.
|
Day 0
|
|
Presence of rhythmic risk markers bye ECG monitoring during games and trainings
Délai: Day 0
|
In case of moderate arrhythmia on stress test and/or Holter ECG, ECG monitoring during training sessions and matches is carried out with analysis of the tracings collected, in search of more sustained arrhythmia, particularly at the ventricular level.
|
Day 0
|
|
Presence of rhythmic risk markers by pharmacological tests and/or electrophysiological exploration
Délai: Day 0
|
If the risk is perceived as very high, pharmacological tests (Isuprel®) and/or electrophysiological exploration may be performed during hospitalization, in search of dangerous rhythm disorders, particularly at the ventricular level.
|
Day 0
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Presence of myocardial fibrosis by injected MRI
Délai: Month 3
|
In order to compare the prevalence of myocardial fibrosis between COVID-19 positive and COVID-19 negative individuals in high level athletes with or without rhythmic risk, a high resolution MRI is performed.
The examinations is performed on 1.5 or 3T MRI systems equipped with specific antennas for cardiology.
The sequence used to detect occult scars is a late enhancement sequence performed at least 15 minutes after injection of gadolinium salts, using a free-breathing 3D method, for a minimum spatial resolution of 2.5x1.25x1.25mm.
The images are reviewed by a core lab at the Bordeaux University Hospital.
The presence or absence of myocardial fibrosis is evaluated.
|
Month 3
|
|
Presence of transmural localization of myocardial fibrosis by injected MRI
Délai: Month 3
|
In order to compare the prevalence of myocardial fibrosis between COVID-19 positive and COVID-19 negative individuals in high level athletes with or without rhythmic risk, a high resolution MRI is performed.
The examinations is performed on 1.5 or 3T MRI systems equipped with specific antennas for cardiology.
The sequence used to detect occult scars is a late enhancement sequence performed at least 15 minutes after injection of gadolinium salts, using a free-breathing 3D method, for a minimum spatial resolution of 2.5x1.25x1.25mm.
The images are reviewed by a core lab at the Bordeaux University Hospital.
The presence or absence of transmural localization is evaluated.
|
Month 3
|
|
Measurement of cardiac scar size by injected MRI
Délai: Month 3
|
In order to compare the prevalence of myocardial fibrosis between COVID-19 positive and COVID-19 negative individuals in high level athletes with or without rhythmic risk, a high resolution MRI is performed.
The examinations is performed on 1.5 or 3T MRI systems equipped with specific antennas for cardiology.
The sequence used to detect occult scars is a late enhancement sequence performed at least 15 minutes after injection of gadolinium salts, using a free-breathing 3D method, for a minimum spatial resolution of 2.5x1.25x1.25mm.
The images are reviewed by a core lab at the Bordeaux University Hospital.
The size of scars is measured in milliliters (mL).
|
Month 3
|
|
Search for constitutional genetic biomarkers
Délai: Month 5
|
identification by sequencing of genetic variants that could have an impact on the occurrence of a severe form in individuals infected with SARS-CoV-2.
|
Month 5
|
|
Research of inflammation markers
Délai: Month 5
|
Th1/Th2/activation/inflammation/apoptosis markers are measured in sera by a Luminex test allowing the detection of 10 analytes with a commercial kit according to the manufacturer's instructions
|
Month 5
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Les enquêteurs
- Chaise d'étude: Antoine BENARD, MD, University Hospital, Bordeaux
- Chercheur principal: Laurent Chevalier, MD, Medical Center of the Bordeaux-Mérignac Sports Clinic
Publications et liens utiles
La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Réel)
18 juin 2020
Achèvement primaire (Réel)
2 mars 2021
Achèvement de l'étude (Réel)
2 mars 2021
Dates d'inscription aux études
Première soumission
2 juin 2021
Première soumission répondant aux critères de contrôle qualité
22 juin 2021
Première publication (Réel)
23 juin 2021
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
23 juin 2021
Dernière mise à jour soumise répondant aux critères de contrôle qualité
22 juin 2021
Dernière vérification
1 juin 2021
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies cardiaques
- Maladies cardiovasculaires
- Infections à coronavirus
- Infections à Coronaviridae
- Infections à Nidovirales
- Infections par virus à ARN
- Maladies virales
- Infections
- Infections des voies respiratoires
- Maladies des voies respiratoires
- Pneumonie virale
- Pneumonie
- Maladies pulmonaires
- Cardiomyopathies
- COVID-19 [feminine]
- Myocardite
Autres numéros d'identification d'étude
- CHUBX 2020/16
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Non
Étudie un produit d'appareil réglementé par la FDA américaine
Non
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .